评估深吸气屏气每日在线自适应放疗治疗中心型肺肿瘤疗效与安全性的II期研究方案(PUDDING研究)
这是一项单中心、单臂II期研究方案,纳入根据国际肺癌研究协会建议诊断的中心型肺肿瘤患者,接受深吸气屏气每日在线自适应放疗。主要终点为按CTCAE v5.0分类的1年3级及以上严重不良事件累积发生率。
要点
- 中心型肺肿瘤因邻近纵隔危及器官, definitive放疗时严重不良事件风险较高。
- 研究采用深吸气屏气联合每日在线自适应放疗的双重方法以降低毒性。
- 主要终点为1年3级及以上不良事件累积发生率(CTCAE v5.0)。
核心结论
- 若深吸气屏气自适应放疗应用于中心型肺肿瘤获得成功,该方法可塑造未来的III期试验并为肺肿瘤放疗提供新视角。
研究设计与样本
- 单中心、单臂II期研究,纳入根据国际肺癌研究协会建议诊断的中心型肺肿瘤患者,接受深吸气屏气每日在线自适应放疗。
主要发现
- 主要终点为按CTCAE v5.0分类的1年3级及以上严重不良事件累积发生率。
- 深吸气屏气通过增加正常肺体积并使肿瘤远离关键纵隔危及器官,提供可测量的剂量学获益,从而减少毒性。
- 深吸气屏气自适应放疗已被提议作为腹部和盆腔癌症的辅助治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Centrally located lung tumours present a challenge because of their tendency to exhibit symptoms such as airway obstruction, atelectasis, and bleeding. Surgical resection of these tumours often requires sacrificing the lungs, making definitive radiotherapy the preferred alternative to avoid pneumonectomy. However, the proximity of these tumours to mediastinal organs at risk increases the potential for severe adverse events. To mitigate this risk, we propose a dual-method approach: deep inspiration breath-hold (DIBH) radiotherapy combined with adaptive radiotherapy. The aim of this single-centre, single-arm phase II study is to investigate the efficacy and safety of DIBH daily online adaptive radiotherapy. METHODS: Patients diagnosed with centrally located lung tumours according to the International Association for the Study of Lung Cancer recommendations, are enrolled and subjected to DIBH daily online adaptive radiotherapy. The primary endpoint is the one-year cumulative incidence of grade 3 or more severe adverse events, as classified by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). DISCUSSION: Delivering definitive radiotherapy for centrally located lung tumours presents a dilemma between ensuring optimal dose coverage for the planning target volume and the associated increased risk of adverse events. DIBH provides measurable dosimetric benefits by increasing the normal lung volume and distancing the tumour from critical mediastinal organs at risk, leading to reduced toxicity. DIBH adaptive radiotherapy has been proposed as an adjunct treatment option for abdominal and pelvic cancers. If the application of DIBH adaptive radiotherapy to centrally located lung tumours proves successful, this approach could shape future phase III trials and offer novel perspectives in lung tumour radiotherapy. TRIAL REGISTRATION: Registered at the Japan Registry of Clinical Trials (jRCT; https://jrct.niph.go.jp/ ); registration number: jRCT1052230085 ( https://jrct.niph.go.jp/en-latest-detail/jRCT1052230085 ).
引用
- Kishi N, Yoneyama M, Inoo H, et al. Protocol of a phase II study to evaluate the efficacy and safety of deep-inspiration breath-hold daily online adaptive radiotherapy for centrally located lung tumours (PUDDING study). Radiat Oncol. 2024. PMID: 38459580. doi:10.1186/s13014-024-02427-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。